Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Fortinet Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.85 (market cap $9.43B), while Fortinet Inc trades at $161.88 (market cap $118.78B). The key difference: Fortinet Inc is far larger — about 12.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap. Which is the better fit depends on your goals.
| BIO | FTNT | |
|---|---|---|
Market Cap | $9.43B | $118.78B |
Sector | Health | Technology |
52-Week High | $356.25 | $168.29 |
52-Week Low | $241.71 | $75.23 |
Enterprise Value | $9.18B | $115.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Fortinet (FTNT) trades at $164.21, up 2.86% in the last session, reflecting strong momentum as it approaches its consensus price target of $174.50. The stock exhibits bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $0.90 versus $0.746 expected. Revenue growth remains robust, climbing to $6.80 billion in 2025, with a net income margin of 28.17%. Recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
The outlook is positive, supported by solid fundamentals and analyst optimism, though elevated valuation ratios like a P/E of 57.2 pose risks. Competition and market volatility are concerns, but institutional buying and bullish ratings suggest further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
